Treatment with Infliximab plus Methotrexate Improves Anemia in Patients with Rheumatoid Arthritis Independent of Improvement in Other Clinical Outcome Measures-A Pooled Analysis from Three Large, Multicenter, Double-Blind, Randomized Clinical Trials

Mittie K. Doyle, Mahboob U. Rahman, Chenglong Han, John Han, Jon Giles, Clifton Bingham, Joan Bathon

Research output: Contribution to journalArticle

Abstract

Objective: To evaluate the effect of antitumor necrosis factor-alpha monoclonal antibody infliximab treatment on anemia in patients with rheumatoid arthritis (RA). Methods: Data from patients with RA who received infliximab or placebo in the multicenter, placebo-controlled, double-blind, randomized ATTRACT, ASPIRE, and START studies were included in this post-hoc, pooled analysis. Infliximab (3 to 10 mg/kg) was administered every 4 or 8 weeks, and all patients received stable doses of methotrexate (MTX). We determined the percentage of anemic patients (baseline hemoglobin level

Original languageEnglish (US)
Pages (from-to)123-131
Number of pages9
JournalSeminars in Arthritis and Rheumatism
Volume39
Issue number2
DOIs
StatePublished - Oct 2009

Fingerprint

Methotrexate
Anemia
Rheumatoid Arthritis
Randomized Controlled Trials
Outcome Assessment (Health Care)
Placebos
Therapeutics
Hemoglobins
Necrosis
Monoclonal Antibodies
Infliximab

Keywords

  • anemia
  • anti-TNF
  • chronic inflammation
  • rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology
  • Anesthesiology and Pain Medicine

Cite this

@article{3773b39d79be48aa95a61d61281067d7,
title = "Treatment with Infliximab plus Methotrexate Improves Anemia in Patients with Rheumatoid Arthritis Independent of Improvement in Other Clinical Outcome Measures-A Pooled Analysis from Three Large, Multicenter, Double-Blind, Randomized Clinical Trials",
abstract = "Objective: To evaluate the effect of antitumor necrosis factor-alpha monoclonal antibody infliximab treatment on anemia in patients with rheumatoid arthritis (RA). Methods: Data from patients with RA who received infliximab or placebo in the multicenter, placebo-controlled, double-blind, randomized ATTRACT, ASPIRE, and START studies were included in this post-hoc, pooled analysis. Infliximab (3 to 10 mg/kg) was administered every 4 or 8 weeks, and all patients received stable doses of methotrexate (MTX). We determined the percentage of anemic patients (baseline hemoglobin level",
keywords = "anemia, anti-TNF, chronic inflammation, rheumatoid arthritis",
author = "Doyle, {Mittie K.} and Rahman, {Mahboob U.} and Chenglong Han and John Han and Jon Giles and Clifton Bingham and Joan Bathon",
year = "2009",
month = "10",
doi = "10.1016/j.semarthrit.2008.08.002",
language = "English (US)",
volume = "39",
pages = "123--131",
journal = "Seminars in Arthritis and Rheumatism",
issn = "0049-0172",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Treatment with Infliximab plus Methotrexate Improves Anemia in Patients with Rheumatoid Arthritis Independent of Improvement in Other Clinical Outcome Measures-A Pooled Analysis from Three Large, Multicenter, Double-Blind, Randomized Clinical Trials

AU - Doyle, Mittie K.

AU - Rahman, Mahboob U.

AU - Han, Chenglong

AU - Han, John

AU - Giles, Jon

AU - Bingham, Clifton

AU - Bathon, Joan

PY - 2009/10

Y1 - 2009/10

N2 - Objective: To evaluate the effect of antitumor necrosis factor-alpha monoclonal antibody infliximab treatment on anemia in patients with rheumatoid arthritis (RA). Methods: Data from patients with RA who received infliximab or placebo in the multicenter, placebo-controlled, double-blind, randomized ATTRACT, ASPIRE, and START studies were included in this post-hoc, pooled analysis. Infliximab (3 to 10 mg/kg) was administered every 4 or 8 weeks, and all patients received stable doses of methotrexate (MTX). We determined the percentage of anemic patients (baseline hemoglobin level

AB - Objective: To evaluate the effect of antitumor necrosis factor-alpha monoclonal antibody infliximab treatment on anemia in patients with rheumatoid arthritis (RA). Methods: Data from patients with RA who received infliximab or placebo in the multicenter, placebo-controlled, double-blind, randomized ATTRACT, ASPIRE, and START studies were included in this post-hoc, pooled analysis. Infliximab (3 to 10 mg/kg) was administered every 4 or 8 weeks, and all patients received stable doses of methotrexate (MTX). We determined the percentage of anemic patients (baseline hemoglobin level

KW - anemia

KW - anti-TNF

KW - chronic inflammation

KW - rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=70349454135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349454135&partnerID=8YFLogxK

U2 - 10.1016/j.semarthrit.2008.08.002

DO - 10.1016/j.semarthrit.2008.08.002

M3 - Article

VL - 39

SP - 123

EP - 131

JO - Seminars in Arthritis and Rheumatism

JF - Seminars in Arthritis and Rheumatism

SN - 0049-0172

IS - 2

ER -